| Similar Articles |
|---|
 |
Bio-IT World
Dec 2006/Jan 2007
Allison Proffitt |
'An Unfortunate Storm': Tripos CEO Discusses Company Future Tripos announced that it has successfully sold its Discovery Informatics business to Vector Capital. Despite the company's difficulties, including a collapsed share price, president and CEO John McAllister is upbeat about the company's future.   |
Bio-IT World
November 2005
Nancy Weil |
Dharmacon, Institutes Form siRNA Global Initiative The company has formed a global alliance with leading biomedical research centers aimed at speeding scientific and medical discoveries now that the first complete siRNA (small interfering RNA) library is available for targeting genes in the human genome. |
Bio-IT World
August 15, 2005
Salvatore Salamone |
Tripos Embraces Web Services To make it easier to incorporate its discovery informatics tools into high-throughput workflows, Tripos has partnered with pipeline vendor SciTegic and announced support for a Web services architecture. |
Bio-IT World
December 15, 2004
Nancy Weil |
Running Interference The revolution in RNA interference has galvanized basic research. Now, some biopharmas are pushing the technology from the laboratory to the clinic. |
Bio-IT World
July 15, 2003
Malorye Branca |
Silence Is Golden RNA interference's scientific, therapeutic, and economic potential is unquestionable, but some sticky questions still remain. |
Chemistry World
October 2, 2006
Bea Perks |
RNAi Pioneers Win Nobel Prize for Medicine Molecular biologists Andrew Fire and Craig Mello have been awarded this year's Nobel prize in physiology or medicine for their discovery of RNA interference. |
Bio-IT World
June 2005
Nancy Weil |
Dharmacon Signs Library Deal The biopharma is providing its genome-wide short-interfering RNA (siRNA) library to Millennium Pharmaceuticals. This is the first commercial siRNA collection that targets genes across the entire human genome, encompassing some 22,000 genes. |
The Motley Fool
October 5, 2006
Ralph Casale |
RNAi: Nobel Prize-Winning Biotechnology While drugs based on RNAi knockdown technology may have the potential to become the next big thing in biotechnology, they are still a long way from becoming FDA-approved marketable entities. But it's never too soon to start keeping an eye on the future. Investors, take note. |
The Motley Fool
August 26, 2009
Brian Orelli |
This One's Growing Through the Recession Sales at Myriad Genetics increased 40% in its recently completed second half of its fiscal year, even if that was a slowdown from the 55% increase in the first half. |
BusinessWeek
February 26, 2007
Gene G. Marcial |
CytRx Can 'Silence' Genes That Cause Disease Since October, shares of CytRx have more than doubled as investors zeroed in on its RNA interference technology that targets diabetes, obesity, and ALS. |
Bio-IT World
March 10, 2003
Mark D. Uehling |
Technology Overload Inundated with new IT tools and mountains of data, the pharmaceutical industry struggles to pull it all together. |
